SWX:OBSN

Stock Analysis Report

Executive Summary

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy.

Snowflake

Fundamentals

Excellent balance sheet with limited growth.

Risks

  • ObsEva has significant price volatility in the past 3 months.

Share Price & News

How has ObsEva's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-1.1%

SWX:OBSN

2.3%

CH Biotechs

-0.5%

CH Market


1 Year Return

-28.0%

SWX:OBSN

-14.1%

CH Biotechs

2.7%

CH Market

OBSN underperformed the Biotechs industry which returned -14.1% over the past year.

OBSN underperformed the Market in Switzerland which returned 2.7% over the past year.


Share holder returns

OBSNIndustryMarket
7 Day-1.1%2.3%-0.5%
30 Day-10.4%-1.7%-2.3%
90 Day-28.6%-4.2%0.6%
1 Year-28.0%-28.0%-13.9%-14.1%8.1%2.7%
3 Yearn/a24.4%21.9%29.4%16.2%
5 Yearn/a70.5%66.0%32.8%12.2%

Price Volatility Vs. Market

How volatile is ObsEva's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is ObsEva undervalued based on future cash flows and its price relative to the stock market?

4.1x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for ObsEva to establish if it is available at moderate discount.

Unable to calculate intrinsic value for ObsEva to establish if it is available at substantial discount.


Price Based on Earnings

ObsEva is loss making, we can't compare its value to the Europe Biotechs industry average.

ObsEva is loss making, we can't compare the value of its earnings to the Switzerland market.


Price Based on Expected Growth

Unable to calculate PEG ratio for ObsEva, we can't assess if its growth is good value.


Price Based on Value of Assets

ObsEva is overvalued based on assets compared to the CH Biotechs industry average.


Next Steps

Future Growth

How is ObsEva expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

-1.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

ObsEva's revenue is expected to grow significantly at over 20% yearly.

ObsEva is not considered high growth as it is expected to be loss making for the next 1-3 years.

ObsEva's revenue growth is expected to exceed the Switzerland market average.

Unable to compare ObsEva's earnings growth to the Switzerland market average as it is expected to be loss making during the next 1-3 years.

Unable to compare ObsEva's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if ObsEva will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.


Next Steps

Past Performance

How has ObsEva performed over the past 5 years?

-40.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

ObsEva does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare ObsEva's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare ObsEva's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if ObsEva has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if ObsEva has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if ObsEva improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is ObsEva's financial position?


Financial Position Analysis

ObsEva is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

ObsEva's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

ObsEva's level of debt (0%) compared to net worth is satisfactory (less than 40%).

Unable to establish if ObsEva's debt level has increased without past 5-year debt data.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 2.342412238188E+17x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

ObsEva has sufficient cash runway for 1.3 years based on current free cash flow.

ObsEva has sufficient cash runway for 1.3 years if free cash flow continues to grow at historical rates of 30.5% each year.


Next Steps

Dividend

What is ObsEva's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate ObsEva's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate ObsEva's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as ObsEva has not reported any payouts.

Unable to verify if ObsEva's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as ObsEva has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of ObsEva's dividends in 3 years as they are not expected to pay a notable one for Switzerland.


Next Steps

Management

What is the CEO of ObsEva's salary, the management and board of directors tenure and is there insider trading?

3.3yrs

Average management tenure


CEO

Ernest Loumaye (67yo)

6.8yrs

Tenure

0

Dr. Ernest Loumaye, MD, PhD, OB/GYN Co-Founded ObsEva SA in November 2012 and has been its Chief Executive Officer since November 2012. Dr. Loumaye co-founded PregLem SA in 2006 and served as its Chief Exe ...


Management Age and Tenure

3.3yrs

Average Tenure

53.5yo

Average Age

The tenure for the ObsEva management team is about average.


Board Age and Tenure

5.6yrs

Average Tenure

57yo

Average Age

The tenure for the ObsEva board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Tim Adams (59yo)

    Chief Financial Officer

    • Tenure: 2.6yrs
  • Mario Corso

    Senior Director of Investor Relations

    • Tenure: 0.0yrs
  • Ernest Loumaye (67yo)

    Co-Founder

    • Tenure: 6.8yrs
  • Jean-Pierre Gotteland (54yo)

    Chief Scientific Officer and Head of R&D

    • Tenure: 3.9yrs
  • Elke Bestel (53yo)

    VP and Head of Drug Safety & Pharmacovigilance

    • Tenure: 3.9yrs
  • Elizabeth Ijeoma Garner (51yo)

    Chief Medical Officer

    • Tenure: 0.1yrs
  • Delphine Renaud

    Personal Assistant to the CSO and Head of R&D

    • Tenure: 0.0yrs
  • Wim Souverijns (48yo)

    Chief Commercial Officer

    • Tenure: 1.1yrs

Board Members

  • Jim Healy (54yo)

    Director

    • Tenure: 6.0yrs
  • Barbara Duncan (54yo)

    Director

    • Tenure: 2.7yrs
  • Rafaèle Tordjman (50yo)

    Vice-Chairperson

    • Tenure: 0.0yrs
  • Frank A. G. Verwiel (57yo)

    Chairperson of the Board

    • Tenure: 2.7yrs
  • Ernest Loumaye (67yo)

    Co-Founder

    • Tenure: 6.8yrs
  • Annette Clancy (65yo)

    Director

    • Tenure: 5.8yrs
  • Jacky Vonderscher (64yo)

    Independent Director

    • Tenure: 5.8yrs
  • Phillip Bennett

    Member of Scientific Advisory Board

    • Tenure: 5.6yrs
  • Ben Mol

    Member of Scientific Advisory Board

    • Tenure: 5.6yrs
  • Vassilis Tsatsaris

    Member of Scientific Advisory Board

    • Tenure: 5.6yrs

Company Information

ObsEva SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ObsEva SA
  • Ticker: OBSN
  • Exchange: SWX
  • Founded: 2012
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$426.696m
  • Listing Market Cap: US$418.145m
  • Shares outstanding: 48.27m
  • Website: https://www.obseva.com

Number of Employees


Location

  • ObsEva SA
  • Chemin des Aulx, 12
  • Plan-les-Ouates
  • Geneva
  • 1228
  • Switzerland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
OBSVNasdaqGS (Nasdaq Global Select)YesCommon SharesUSUSDJan 2017
OBSV NBMV (Bolsa Mexicana de Valores)YesCommon SharesMXMXNJan 2017
OBSNSWX (SIX Swiss Exchange)YesCommon SharesCHCHFJan 2017
22DDB (Deutsche Boerse AG)YesCommon SharesDEEURJan 2017

Biography

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Li ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/18 22:09
End of Day Share Price2019/08/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.